Last viewed:
LIFE
Prices are updated after-hours
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
(0.0% 1d)
(-15.6% 1m)
(-21.0% 1y)
(0.0% 2d)
(-1.2% 3d)
(0.0% 7d)
(-18.82%
volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 108,365,641
http://www.atyrpharma.com
Sec
Filling
|
Patents
| 44 employees
(US) aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
glass
diagnostics
add to watch list
Paper trade
email alert is off
Press-releases
aTyr Pharma to Participate in April Investor Conferences
Published: 2024-04-01
(Crawled : 12:00)
- globenewswire.com
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| -18.59%
| O: -1.01%
H: 0.0%
C: -3.05%
pharma
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Published: 2024-03-14
(Crawled : 20:00)
- globenewswire.com
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| 0.0%
| O: 0.0%
H: 24.07%
C: 22.84%
pharma
year
update
results
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Published: 2024-02-28
(Crawled : 13:00)
- globenewswire.com
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| -19.0%
| O: 0.0%
H: 1.5%
C: -5.0%
pharma
conference
year
financial
results
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
Published: 2024-02-21
(Crawled : 13:00)
- globenewswire.com
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| -13.83%
| O: 1.6%
H: 5.24%
C: 3.14%
pharma
program
trial
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
Published: 2024-01-29
(Crawled : 13:00)
- globenewswire.com
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| 2.53%
| O: 0.0%
H: 3.16%
C: 2.53%
pharma
cell
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
Published: 2024-01-18
(Crawled : 13:00)
- globenewswire.com
WDAY
A
|
$255.73
-0.42%
-0.43%
1.2M
|
Technology Services
| -8.71%
| O: 0.71%
H: 0.87%
C: 0.84%
PODD
|
$167.215
-0.03%
-0.03%
650K
|
Health Technology
| -16.74%
| O: 0.95%
H: 0.87%
C: 0.54%
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| 11.34%
| O: 1.72%
H: 0.0%
C: -4.05%
pharma
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
Published: 2023-11-13
(Crawled : 13:00)
- globenewswire.com
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| 44.64%
| O: -1.79%
H: 6.36%
C: 1.36%
pharma
preclinical
efzofitimod
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
Published: 2023-11-09
(Crawled : 21:00)
- globenewswire.com
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| 40.87%
| O: 0.87%
H: 0.86%
C: -3.45%
pharma
update
results
Sarcoidosis Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Key Players - Pfizer, United Therapeutics, Xentria, aTyr Pharma, Kyorin Pharmaceutical, Novartis, Kinevant Sciences
Published: 2023-11-02
(Crawled : 21:00)
- prnewswire.com
UTHR
|
$237.06
1.11%
1.09%
610K
|
Health Technology
| 2.76%
| O: 0.73%
H: 0.63%
C: -2.35%
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| 25.58%
| O: 0.78%
H: 1.54%
C: 0.0%
sciences
growth
market
aTyr Pharma to Present at November Investor Conferences
Published: 2023-11-01
(Crawled : 12:00)
- globenewswire.com
LIFE
|
$1.595
-1.54%
-1.57%
290K
|
Health Technology
| 29.6%
| O: 5.6%
H: 0.0%
C: -6.82%
pharma
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001209191-24-002949
4
2024-02-07
2024-02-05
Sell
M
10375
20750
0001209191-24-002949
4
2024-02-07
2024-02-05
Buy
M
10375
116548
0001209191-24-002947
4
2024-02-07
2024-02-05
Sell
M
3750
7500
0001209191-24-002947
4
2024-02-07
2024-02-06
Sell
S
1590
20821
0001209191-24-002947
4
2024-02-07
2024-02-05
Buy
M
3750
22411
0001209191-24-002945
4
2024-02-07
2024-02-05
Sell
M
2688
5374
0001209191-24-002945
4
2024-02-07
2024-02-05
Buy
M
2688
14767
0001209191-24-001302
4
2024-01-10
2024-01-05
Buy
A
600000
600000